Nabi Biopharmaceuticals is focused on developing products that address unmet medical needs and offer opportunities in our core business areas: nicotine addiction and gram-positive bacterial infections. Driven by our clinical development programs, we are focused on building value for our vaccine programs: NicVAX (Nicotine Conjugate Vaccine) and EnteroVAX™ (Enterococcus faecalis Conjugate Vaccine). Our headquarters is located in Rockville, Maryland along with our Research and Development facility.